Leerink Partnrs Increases Earnings Estimates for NeuroPace

NeuroPace, Inc. (NASDAQ:NPCE) – Equities research analysts at Leerink Partnrs boosted their FY2024 earnings per share estimates for shares of NeuroPace in a report released on Tuesday, November 12th. Leerink Partnrs analyst M. Kratky now anticipates that the company will post earnings per share of ($1.03) for the year, up from their prior estimate of ($1.10). The consensus estimate for NeuroPace’s current full-year earnings is ($1.08) per share. Leerink Partnrs also issued estimates for NeuroPace’s Q4 2024 earnings at ($0.27) EPS, Q1 2025 earnings at ($0.30) EPS, Q2 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.22) EPS and FY2025 earnings at ($1.03) EPS.

NPCE has been the subject of a number of other reports. Wells Fargo & Company dropped their price target on shares of NeuroPace from $15.00 to $13.00 and set an “overweight” rating for the company in a research report on Wednesday. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $18.00 target price on shares of NeuroPace in a report on Wednesday, August 14th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $14.60.

NeuroPace Stock Up 5.8 %

Shares of NASDAQ:NPCE opened at $9.68 on Friday. NeuroPace has a 12-month low of $5.45 and a 12-month high of $18.15. The stock has a 50 day moving average of $6.89 and a 200 day moving average of $7.51. The company has a current ratio of 5.59, a quick ratio of 5.47 and a debt-to-equity ratio of 6.03.

NeuroPace (NASDAQ:NPCE) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.03. The firm had revenue of $19.26 million for the quarter, compared to the consensus estimate of $18.30 million. NeuroPace had a negative return on equity of 205.41% and a negative net margin of 36.74%. The business’s revenue for the quarter was up 16.6% compared to the same quarter last year. During the same quarter last year, the company earned ($0.36) earnings per share.

Hedge Funds Weigh In On NeuroPace

Several institutional investors have recently added to or reduced their stakes in NPCE. Financial Advocates Investment Management raised its holdings in shares of NeuroPace by 20.0% during the 3rd quarter. Financial Advocates Investment Management now owns 18,000 shares of the company’s stock worth $125,000 after acquiring an additional 3,000 shares in the last quarter. Millennium Management LLC raised its stake in NeuroPace by 13.3% during the second quarter. Millennium Management LLC now owns 686,037 shares of the company’s stock valued at $5,186,000 after purchasing an additional 80,324 shares in the last quarter. XTX Topco Ltd lifted its position in NeuroPace by 56.1% during the second quarter. XTX Topco Ltd now owns 24,055 shares of the company’s stock valued at $182,000 after purchasing an additional 8,643 shares during the last quarter. Acadian Asset Management LLC grew its stake in shares of NeuroPace by 46.0% in the 2nd quarter. Acadian Asset Management LLC now owns 68,918 shares of the company’s stock worth $520,000 after buying an additional 21,703 shares in the last quarter. Finally, Rhumbline Advisers bought a new stake in shares of NeuroPace in the 2nd quarter worth about $111,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

Insider Activity

In other news, major shareholder Ltd. Kck sold 223,991 shares of NeuroPace stock in a transaction dated Friday, October 25th. The stock was sold at an average price of $5.45, for a total value of $1,220,750.95. Following the sale, the insider now directly owns 5,270,845 shares of the company’s stock, valued at approximately $28,726,105.25. The trade was a 4.08 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have sold a total of 257,590 shares of company stock worth $1,437,916 over the last quarter. Insiders own 22.20% of the company’s stock.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.